STRIDE-III: updated treatment targets in IBD

Alessandro Armuzzi from Milano, Italy gives an exciting overview about current and future treatment options in IBD and also a look into the pipeline. Oral and parenteral options are discussed and the potential use of the available options in our current treatment paradigms

Axel Dignass, Coordinator and senior author of STRIDE-III and host of IBD Essentials talks about development and key findings of the updated STRIDE-III framework, presented as latebreaker at UEGW 2026 in Barcelona and published on October 19/2026 in Lancet Gastroenterol Hepatol 2026; doi:10.1016/S2468-1253(26)00292-X

Nuru Noor, lead investigator of the Profile Study from the UK talks about the design and results of the Profile Study including longterm data and also about the concepts of early treatment, topdown strategies versus stepup approaches and prediction of disease courses in IBD

Andreas Münch from Linköping, Sweden, a leading expert in microscopic colitis talks about his journes in the area of microscopic colitis, management of microscopic colitis and the development of international guidelines on microscopic colitis

Uma Mahadevan about Pregnancy in IBD

Iris Dotan talks to Rupa Banerjee about the evolving landscape of inflammatory bowel disease (IBD) in India. Together, they explore current trends, challenges in diagnosis and treatment, and how the management of IBD is developing across the country. The conversation also highlights regional perspectives, clinical experiences, and what the future may hold for patients with IBD in India.

Iris Dotan and Mette Julsgaard about Pregnancy in IBD

Taku Kobayashi from Tokyo talks about special aspects of IBD management in Japan, monitoring strategies and medical treatment in Japanese IBD patients including apheresis, tacrolimus, differences in the diseae course of Japanese and European patients with IBD and different managment strategies

Florian Rieder from Cleveland Clinic, Cleveland, USA, internationally renowned IBD, intestinal fibrosis expert and principal investigator of the new treatment option with the oral GI-restricted small molecule inhibitor of ALK-5 Ontunisertib in fibrostenosisng CD

Paulo Kotze, Curtiba, Brazil, talks about special aspects of IBD management in South America, Early Surgery in Crohn's disease, appendectomy as a new treatment option in ulcerative colitis and the emerging role of robotic surgery in IBD surgery